Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tucatinib + trastuzumab + mFOLFOX6 versus standard first-line therapy in HER2-positive metastatic colorectal cancer
CTR20230081Phase 3Active
- Sponsor
- MSD
- Start
- Apr 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of tucatinib, trastuzumab, oxaliplatin, folinic acid, fluorouracil in colorectal adenocarcinoma, sponsored by MSD. Started Apr 2023; status: active.
02
Drugs
03
Conditions
colorectal adenocarcinoma
Beyond the preview
Go deeper on CTR20230081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230081.